1357294-64-4

Upstream product

• 99-94-5 p-Toluic acid 
• 5004-88-6 4,5-dimethoxyanthranilamide 
• 874-60-2 4-methyl-benzoyl chloride 

Downstream Products

• 228118-78-3 6,7-dimethoxy-2-p-tolylquinazolin-4(3H)-one 
• 228118-80-7 4-chloro-6,7-dimethoxy-2-(4-methylphenyl)quinazoline 
• 1357295-00-1 4-azido-6,7-dimethoxy-2-p-tolylquinazoline 
• 1357295-06-7 6,7-dimethoxy-2-(p-tolyl)quinazolin-4-amine 

Relevant academic research and scientific papers

6,7-dimethoxyquinazolines as potential cytotoxic agents: Synthesis and in vitro activity

It has been reported that 6,7-dimethoxyquinazoline derivatives have cytotoxic potential independent of their a1-adrenoceptor blocking potential. Bioisosteres of 2-arylquinazolines are considered to have anti-tumor properties. In the present study, we have synthesized the 2-aryl and 2-arylmethyl derivatives of quinazolin-4(3H)-one while retaining the 6,7-dimethoxy substituents. Derivatives with n-butyl group attached to position-3 of quinazolinone nucleus were synthesized with the aim of increasing their lipophilicity. The potential of these synthesized compounds was evaluated against NCI (National Cancer Institute) 60 cell panel using the NCI disease oriented antitumor screen protocol. Based on the results of this screening we generalized that compounds having aryl groups directly attached to the quinazoline ring are less active than those which have one atom linker in between the two ring systems. Substitution of a lipophilic group like nbutyl decreases cytotoxic activity among the compounds and 4-aminoquinazolines showed better activity than 4-quinazolinones. Lipophilic groups in the aromatic ring yielded more active compounds as cytotoxic agents. Among the selected compounds, 4h and 13b were found to be potential lead compounds which could be further optimized as potential anti-neoplastic agents.

Cytotoxic potential of novel 6,7-dimethoxyquinazolines

Herein, we report the synthesis and cytotoxicity of a series of substituted 6,7-dimethoxyquinazoline derivatives. The cytotoxic activity of all synthesized compounds has been evaluated against HCT116p53+/+ and HCT116p53 -/- colon cancer cells and a HEY ovarian cancer cell line naturally resistant to cisplatin. Nine of the tested compounds showed significant cytotoxicity in all cell lines at 10 μM. The most promising derivative (7c) showed IC50values of 0.7 and 1.7 μM in the two colon cancer cell lines.